FibroGen files for IPO

FibroGen Inc. (San Francisco, Calif.) filed to raise up to $125 million in an IPO on NASDAQ underwritten by Goldman, Sachs; Citigroup; Leerink; RBC; Stifel; and William Blair.

FibroGen's lead compound is roxadustat ( FG-4592, ASP1517), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase ( HIF-PH; EGLN) in Phase III testing to treat anemia in chronic kidney disease. Astellas Pharma Inc. (Tokyo:4503) has rights to roxadustat from FibroGen in Japan, Europe, the Commonwealth of Independent States (CIS), the Middle East and South Africa. FibroGen and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to develop and commercialize roxadustat worldwide, excluding the countries in which Astellas already has rights. ...